Metabolic Bone Disease News and Research

RSS

Correcting vitamin D deficiency before orthopedic surgery improves patient outcome: Study

Almost 50 percent of patients undergoing orthopedic surgery have vitamin D deficiency that should be corrected before surgery to improve patient outcomes, based on a study by researchers at Hospital for Special Surgery (HSS) in New York City. Vitamin D is essential for bone healing and muscle function and is critical for a patient's recovery. The study appears in the October issue of The Journal of Bone and Joint Surgery.

8 Oct 2010

Vitamin D deficiency may impact orthopaedic procedure outcomes

Forty-three percent of patients scheduled to undergo orthopaedic surgery have insufficient levels of vitamin D and two out of five of those patients had levels low enough to place them at risk for metabolic bone disease, according to a study published this month in the October 6th issue of the Journal of Bone and Joint Surgery (JBJS).

7 Oct 2010

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

24 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Hospital for Special Surgery named top hospital for orthopedics

Hospital for Special Surgery has been named the top hospital in the nation for orthopedics by U.S. News & World Report in its 2010 "America's Best Hospitals" issue. Once again the hospital ranked as a leader in rheumatology at number 3 in the nation. In addition, neurology was ranked at number 16.

15 Jul 2010

Enobia reports positive interim data from ENB-0040 enzyme replacement therapy study for children with HPP

Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO 2010, the 92nd Annual Meeting of The Endocrine Society.

22 Jun 2010

Enobia Pharma unveils findings from first HPP self-reported patient survey at ACMG 2010

Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.

30 Mar 2010

Extended treatment with active ingredient increases bone volume and calcium content

Genta Incorporated today announced publication of two scientific studies that test the active ingredient in Genta’s program to develop orally available gallium-containing compounds and the Company’s marketed product, Ganite® (gallium nitrate for injection).

13 Jan 2010

2009 Ward Burdick Award for UAB Director

The director of the University of Alabama at Birmingham (UAB) Center for Metabolic Bone Disease has won the 2009 Ward Burdick Award for Distinguished Service to Clinical Pathology from the American Society for Clinical Pathology (ASCP).

9 Dec 2009

Gluten-free diet leads to complete recovery of bone mineralization in CD affected children

Celiac disease (CD) is an inherited intestinal disorder characterized by life-long intolerance to the ingestion of gluten, a protein found in wheat, rye, and barley. Although CD can be diagnosed at any age, it commonly occurs during early childhood (between 9 and 24 months). Reduced bone mineral density is often found in individuals with CD.

9 Oct 2009

Book on pediatric bone disorders and mineral metabolism

Summarizing current knowledge, the physiology of calcium, magnesium and phosphate metabolism, the technique of bone biopsy and uses and pitfalls of bone density scanning are discussed. The main part of this publication describes in detail the disorders associated with hypocalcemia, hypercalcemia, rickets, phosphate metabolism, primary and secondary osteoporosis. The genetic nature of many of these conditions is highlighted and each condition is referred to by the number of its OMIM entry. The final chapter, which distinguishes this book from previous publications on the topic, comprises case reports illustrating some of the problems that are examined in previous chapters.

21 Sep 2009

Enobia Pharma's clinical study of ENB-0040 for treating hypophosphatasia provides positive results

Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor development.

14 Sep 2009

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

2 Sep 2009

Metabolic bone disease in cirrhosis patients

Long-standing liver disease has long been recognized to result in fragile bones with increased risk of fractures. In various international studies, the overall incidence has varied from 11% to 48%, with a fracture rate of 3%-44%.

10 Aug 2009

Study identifies causes of bone loss in breast cancer survivors

Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

19 Nov 2008

Can long-term use of Fosomax hinder bone healing?

There is new evidence linking risk for one kind of fracture with long-term use of bisphosphonates -- drugs like Fosamax that are prescribed to treat osteoporosis in older persons by increasing bone density in order to prevent fractures.

26 Jun 2008

First study to examine vitamin D insufficiency in pediatric patients with low bone density

Vitamin D insufficiency is common in adults and is emerging in the world of pediatrics. A mild degree of vitamin D deficiency, also known as vitamin D insufficiency, causes rickets in children and can be treated with increased amount of nutritional vitamin D intake as well as increased sun exposure.

2 Jun 2008

Genta and Emisphere Technologies file investigational new drug exemption

Genta Inc. and Emisphere Technologies, Inc. have jointly announced the submission of an Investigational New Drug Exemption (IND) to the Endocrinologic and Metabolic Drugs Division of the U.S. Food and Drug Administration (FDA) for a new drug known as G4544.

2 Aug 2007

Bariatric surgery - possible treatment for type 2 diabetes mellitus

What role could bariatric surgery possibly play as a treatment for type 2 diabetes mellitus? This topic and several others will be discussed at the American Association of Clinical Endocrinologists (AACE) Sixteenth Annual Meeting & Clinical Congress, Thursday, April 12, 2007 at the Washington State Convention & Trade Center in Seattle.

5 Apr 2007

Link between lead and osteoporosis strengthens

Bolstered by recent laboratory findings, researchers at the University of Rochester Medical Center are embarking on a National Institutes of Health-funded clinical study to better understand the deceptive role environmental lead exposure plays in bone maturation and loss.

4 Apr 2006